Efficacy of Oral Apremilast in the Treatment of Alopecia Areata at the Tertiary Care Hospital, Karachi.
- Sponsor
- Jinnah Postgraduate Medical Centre
- Study ID
- NCT05926882
- Phase
- PHASE4
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 20 Years - 70 Years
- Healthy Volunteers
- Accepted
Interventions
- Apremilast 30mg — DRUGPatients will be given Oral Apremilast 30 mg twice daily after 05 days titration dose.
Study Details
Alopecia areata (AA) is a disease characterized by hair cycle dysfunction and the presence of peribulbar and perifollicular mononuclear cell infiltrate.1 The majority of patients report the rapid onset of one or several well-defined, usually round, 1 to 4 cm areas of scalp hair loss. A common feature is the presence of "exclamation-mark" hairs that are broken and short hairs that taper proximally. Commonly used treatment modalities are steroids (intra-lesional, topical or systemic), contact immunotherapy, anthraline, minoxidil, calcineurine inhibitors, topical retinoids, systemic immune modulating agents, photo-chemotherapy, dermatography wigs and hypnotherapy etc Apremilast is a newer drug. It is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4), this may be effective treatment for a variety of inflammatory skin disorders such as alopecia areata.
Key Dates
- First listed
- Jul 3, 2023
- Start date
- Aug 1, 2022
- Status verified
- Jun 2023
- Primary completion
- Jun 20, 2023
- Completion
- Jun 20, 2023
Study Design
- Enrollment
- 30 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Apremilast tabletPatients will be given Oral Apremilast 30 mg twice daily after 05 days initial titration dose. The effect of treatment will be evaluated using photographs of the patients before and after the study and clinical evaluation of patients.
Primary Outcome Measure
Efficacy of Oral Apremilast in the treatment of Alopecia Areata at the Tertiary Care Hospital, Karachi [ Time Frame: It will be assessed upto 12 weeks ]
Related Studies
- Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia AreataPHASE2 · Recruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland
- Regeneron AA Multicenter (Dupilumab)PHASE2 · Recruiting · Emma Guttman · Irvine, California
- CorEvitas Alopecia Areata (AA) Safety and Effectiveness RegistryRecruiting · CorEvitas · Waltham, Massachusetts
- Dupilumab in the Treatment of Pediatric Alopecia AreataPHASE2 · Recruiting · Icahn School of Medicine at Mount Sinai · Irvine, California